Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Corporation's Shares Plunged 31% in January

By Brian Feroldi - Feb 9, 2016 at 9:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was a crazy month for the beaten-down biotech.

January was a crazy month for investors in MannKind (MNKD 1.15%). A flurry of news releases sent shareholders on a roller-coaster ride. The company's stock ended up losing more than 31% of its value during the month, according to data from S&P Capital IQ.

MNKD Chart

MannKind flooded investors' inboxes with news releases during the month. Here's a quick recap of what transpired.

Jan. 5: Sanofi announced that it was terminating its partnership with MannKind and would be handing Afrezza's commercialization responsibilities back to MannKind over the coming months. Afrezza, an inhaled insulin, is MannKind's only approved drug, so the company was so heavily dependent on Sanofi's deep pockets to turn it into a success. When the news broke, shares lost nearly half of their value and closed below $1 per share.

Jan. 6: Piper Jaffray analyst Joshua Schimmer predicted that the company wouldn't be able to make it without Sanofi in its corner and said the company will head toward bankruptcy. He set a price target of only $0.05 for the company's stock. 

Jan. 11: MannKind promoted CFO Matthew Pfeffer to the top seat, permanently filling the void left by his predecessor, who was ousted in November.

Jan. 13: At the J.P. Morgan Healthcare Conference, Pfeffer laid out his ideas on how the company will proceed from here, which included potentially leaning heavily on social media as a low-cost method for marketing Afrezza. 

Jan. 21: MannKind inked a deal with with Receptor Life Sciences -- a "newly formed entity" -- worth up to $102.25 million if all development and commercialization milestones are met. Shares rose.

Jan. 26: MannKind released more details on its site about its deal with Receptor. Shares rallied again.

Jan. 27: Shares jumped after Reuters reported that the company is "exploring strategic options, including the sale of itself."

Now what?
MannKind's future remains a mystery. It's unknown whether the company's new marketing strategy will help turn Afrezza's fortune around. It's also possible that someone could swoop in and buy the whole company, but there are plenty of reasons to be skeptical that such a deal would happen.

With so many questions up in the air, MannKind's stock is likely to continue to be extremely volatile into the foreseeable future. Bulls and bears alike should proceed with caution.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$3.98 (1.15%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.